Adimmune Group today announced major business progress. Enimmune’s (TWSE: 6564) EnVAX-A71, the first Taiwan locally developed and manufactured vaccine against enterovirus 71, has received the Market Authorization from TFDA. Collaboration to explore the ASEAN market through clinical trials is being discussed with potential partners. Secondly, benefited from the sales of influenza vaccine to Eastern Europe and the passing of EU’s inspection for the second automated aseptic filling and packaging line in 2022, Adimmune (TWSE: 4142) is achieving sustainable growth in global CDMO orders and revenue. 

Employing Adimmune’s high capacity manufacturing facility which utilizes cell culture bioreactors, Enimmune EnVAX-A71 vaccine is EV71 B4 virus-based, the circulating strain in Taiwan, and is also shown to be effective against the prevalent strains in Southeast Asia and China.  

“EnVAX-A71 is scheduled to be available in Taiwan in 2023 Q1. We will soon start the promotion campaign in hospitals and clinics along with our strategic partners in the medical communities,” said Vic Chang, President of Enimmune Corp. “For the overseas market, EnVAX-A71 has obtained the Halal certification, and we are conducting a Phase 3 clinical trial in Vietnam. We have signed a marketing and sales MOU with Vietnam’s largest state-owned vaccine company, and are targeting to protect children in Asia which is estimated to require over 20 million doses per year.” 

As of Adimmune’s CDMO business, to deepen the cooperation with the partner in Eastern Europe, the sales of influenza vaccine supplied by Adimmune are expected to reach Central Asia through Eastern Europe. This year’s order for influenza antigen is expected to double, while Techdow’s order increased sixfold compared to 2022. For the SCD’s intravitreal injection solution for macular degeneration, Adimmune has finished process development last year and is looking to start commercial production in the second half of 2023. “Even in this time of uncertainty, in the past two years Adimmune has reached the sales goals and achieved sustainable growth,” said Chi-Hsien Chan, Chairman and CEO of Adimmune Corporation. “This year, we will continue to capture new opportunities for cross-border cooperation and strive for technology upgrade, to ensure solid growth and globalization as well as the health of the public in Taiwan.”